Maggie L. Shaw

A virologist and physician-scientist at Johns Hopkins Medicine, Annie Antar, MD, PhD, will be presenting research on Long COVID and viral rebound and clearance at the 2025 Conference on Retroviruses and Opportunistic Infections, taking place March 9-12 in San Francisco. […]

Polycythemia vera is a classic myeloproliferative neoplasm and a chronic type of leukemia, which often leads to overproduction of various blood cells. Several medications are approved to treat this condition—among them ruxolitinib (Jakafi; Incyte), in December 2014,1 and ropeginterferon alfa-2b-njft

Negative is how many patients with disabilities report their interactions with health care professionals (HCPs), particularly the ability to comprehensively understand complex health information when living with a vision, hearing, or cognitive disability, according to research published online today in

Cervical cancer is on the rise in the US, according to recent data,1,2 but certain populations of patients in the country may be at a greater disadvantage for worsened outcomes: women who live in a rural location vs an urban

The ongoing call for research and studies to better reflect a real-world population has never been more important, with experts from across the medical community—from the psoriatic arthritis and prostate cancer spaces to patient navigation experts—sounding the alarm on enhancing

Patients in England newly diagnosed with myasthenia gravis receive subpar care due to inconsistent treatment, delayed diagnosis, and limited disease awareness, hindering optimal management of this chronic autoimmune condition through effective disease control. According to new research published in Journal

On March 11, 2020, the World Health Organization officially declared the COVID pandemic, following reports of more than 118,000 cases in 114 countries and a 3.6% mortality rate.1 In the 5 years since, much has been investigated, analyzed, and learned

From a region in the rural South already beset by extreme poverty and high rates of poor health outcomes—such as cardiovascular disease, hypertension, obesity, hypercholesterolemia, and diabetes1-3—comes a new report detailing cervical cancer prevention failures and care shortcomings prevalent among

Cemacabtagene ansegedleucel (cema-cel; Allogene Therapeutics) has robust data that reinforce its durability, effectiveness, and safety as an allogeneic chimeric antigen receptor (CAR) T-cell therapy for patients who have relapsed/refractory large B-cell lymphoma, a type of non-Hodgkin lymphoma. The 2-year results—the

Karen Winkfield, MD, PhD, the Ingram Professor of Cancer Research at Vanderbilt Ingram Cancer Center, professor of medicine at Meharry Medical College, and executive director of the Meharry-Vanderbilt Alliance, discusses the importance of research that extends beyond academia to be